Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab breast milk concentration study in lactating participants
2025-522362-78-00Phase 4Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 4, open-label, single-arm trial of mirikizumab in autoimmune colitis and Crohn's disease, sponsored by Eli Lilly and Company. Primary endpoint: Mirikizumab concentration in breast milk. Planned start Jun 2026; status: authorised.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2025-522362-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522362-78-00.